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achieving European and Adult Treatment Panel III (ATP Ill) LDL-C goals and analysis of 
variance for percentage change from baseline in lipid measures. 
Results: Results at wks 8 (RIO vs Al0 & A20) and 16 (switch groups) were: 
80 and 160 mg doses of pravastatin. The incremental efficacy benefit on mean LDL-C 
was 6% (-37% vs -45%) for pravastatin 80 and 160 mg. Safety was not compromised 
with higher doses of pravastatin therapy. 
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Results favoring RlO over the other statins ware seen at wks 8 and 16. Over 16 wks, all 
treatments ware well tolerated, with similar adverse event cccurrence rates. 
Conclusion: In patients requiring aggressive lipid-modifying therapy, switching from 
atorvastatin to mg-equivalent doses of rosuvastatin brought more patients within interna- 
tional LDL-C treatment guidelines. 
1010-150 Effect of Pravastatin on Low-Density Lipoprotein 
Particle Concentration as Determined bv Nuclear 
Magnetic Resonance Spectroscopy: Rekts From the 
Pravastatin InflammationKRP Evaluation (PRINCE) 
Trial 
Gavin J. Blake, Michelle A. Albert, Nader Rifai, Paul M. Ridker, Brigham &Women’s 
Hospital. Boston, MA 
Background: The effect of statin therapy on LDL partlcle concentration, as determined 
by Nuclear Magnetic Resonance (NMR) spectroscopy, is not well-established. Methods: 
NMR-determined levels of LDL particle concentration and LDL size. as well as standard 
chemical lipid parameters, were measured at baseline and after 12 weeks among 500 
individuals randomly allocated to pravastatin 40mg (n=256) or placebo (n=244). 
Results: Randomization to pravastatin therapy caused a significant reduction in median 
LDL particle concentration (1539.5 nmol/L at baseline to 1264.5 nmollL at 12 weeks, % 
change = 19.0%, p<O.OOOl), as compared to a 24.9% change in LDL cholesterol mea- 
sured chemically. Pravastatin therapy did not cause a significant change in median LDL 
size (20.8 nm at baseline YS 20.9 nm at 12 weeks, % change = 0.5%, p=O.l3). The 
change in LDL particle concentration with pravastatin therapy correlated inversely with 
baseline LDL size (w0.24; p<O.OOOl) such that the largest reduction in LDL particle con- 
centration was among those with the smallest LDL size at baseline (% change = 21.4% 
for tertile 1 of LDL size, 19.9% for tertile 2, and 16.5% for tertile 3; p = 0.03). In contrast, 
pravastatin-induced changes in LDL cholesterol did not correlate with baseline LDL we 
(r=-0.03; p=O.61). 
Conclusions: Randomized allocation to pravastatin (40mg) therapy for 12 weeks 
caused a reduction in LDL particle concentration, the magnitude of which was dependent 
on baseline LDL size. 
1010-151 Efficacy and Safety of Pravastatin at 60 mg and 160 mg 
Robert S. Rosenson, High-Dose Pravastatin Invesbgators, Northwestern University, The 
F&berg School of Medicine, Chicago, IL 
Background: Although safety and clinical efficacy have been well established with prav- 
a&tin 40 mg daily, experience with higher doses has not been reported. 
Methods: This was a randomized, double-blind, placebo-controlled, parallel-dose trial to 
evaluate the cholesterol-lowering efficacy, safety and tolerability of pravastatin for 6 
weeks at doses of 40 mg, 80 mg, or 160 mg once daily in men and women 24 to 65 years 
of age, with primary hypercholesterolemia (LDL-C z 160 mgldL and TG < 500 mg/dL) 
and no history of prvx cardiovascular disease. 
Results: 189 subjects (143 pravastatin, 46 placebo) were eligible for randomization to 
active treatment. At 6 weeks pravastatin signlftcantly reduced LDL-C by 29% at 40 mg (p 
< O.OOl), 37% at 80 mg (p < 0.001) and by 45% at 160 mg (p < 0.001) from baseline. 
This reduction was in a dose-dependent manner, whereas mean LDL-C I” the placebo 
group declined by a non-significant 3%. Beneficial dose-dependent decreases were also 
demonstrated for total cholesterol (p < O.OOl), and TG (p < 0.001) in pravastabn-treated 
subjects over the dosage range 40 to 160 mglday at 6 weeks; however, increases in 
HDL-C (p = 0.47) were not dose dependent. Most treatment-related adverse events were 
mild or moderate in intensity, with only 2 (1.4%) subjects in the pravastatin 160 mg group 
discontinuing for gastrointestinal events and 1 (2.2%) placebo-treated subject discontinu- 
ing for headache and fatigue. One subject each in the placebo (2.2%) and pravastatin 40 
mg (2.2%) groups experienced a creatmme kinase elevation > 4 times the upper limit of 
normal. 
Conclusion: This clinical study demonstrates the incremental lipid-lowering efficacy of 
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1011-134 Selective Estrogen Receptor Modulator Raloxifene 
Inhibits the Cardiac Hypertrophy and Dysfunction Due 
to Aortic Banding in Mice 
Hisakazu Oaita, Koichi Node, Hiroshi Asanuma, Shoji Sanada, Seijl Takashima, Tetsuo 
Minamino. Masanori Asakura, Jiyoong Kim, Yulin Liao, Yoshihiro Asano, Yasunori 
Shintani, Ken-ichiro Okada. Masashi Fujita, Aklo Hirata. Osamu Tsukamoto, Masatsugu 
Hod. Masafumi Kltakaze, Osaka University Graduate School of Medicine, Suita, Japan, 
National Cardiovascular Center, Suita, Japan 
Background: 17kEstradiol reduces myocardial hypertrophy and left ventrkxlar mass. 
However, it is not reported whether the selective estrogen receptor modulator, raloxifene. 
inhibits cardiac hypertrophy and dysfunction. Methods: We used transverse aorw 
banded mice to produce pressure-overload cardiac hypertrophy and neonatal rat ventric- 
ular cardiomyocyles to Investigate the cellular mechanisms of raloxifene on cardiac 
hypertrophy. Both left ventricular mass and fractional shortening of mice were measured 
by echocardiography. Protein synthesis of cardiomyocytes was evaluated by incorpora- 
tion of [3H]-leucine Into cardiomyocytes exposed to several agonists (either angiotensin- 
II, phenylephrine or epinephrine) of cardiac hypertrophy. Intracellular signaling in cardi- 
omyocytes was also observed by mitogen-actnated protein (MAP) kinase assay. 
Results: Raloxlfene prevented both increases I” left ventricular mass (raloxifene (+): 
75*19 mg vs. raloxifene (-): 117+11 mg, ~~0.05). and decreases of fractional shortening 
(raloxifene (+): 38*2 % vs. raloxifene (-): 31*2 %, p<O.Ol) 4 weeks after aortic banding. 
Pretreatment with raloxifene prior to hypetirophic stimulation inhibited the increase of 
[sH]-leucine incorporation into cardiomyocytes in a concentration-dependent manner. 
This effect was partially attenuated by ti-nitro-L-arginine methyl ester (L-NAME), an 
inhIbItor of NO synthase, and completely abolished by lCll82760, an estrogen receptor 
antagonist. Although activities of p38 MAP kinase, c-Jun NH,-terminal protein kinase 
(JNK) and extracellular signal-regulated protein kinase (ERK) significantly increased 10 
minutes after hyperirophic stimulation to cardiomyocytes compared with the control, pre- 
treatment with raloxifene attenuated p38 MAP kinase activity, but neither JNK nor ERK 
actwities. Conclusion: Raloxifene inhibits cardiac hypertrophy and dysfunction, and the 
stimulatatton of estrogen receptors followed by the inhibition of p38 MAP kinase activity 
may be involved in the cellular mechanism. 
1011-135 Prognostic Significance of Left Ventricular Hypertrophy 
During Treatment of Hypertension: The LIFE Study 
Richard B. Deverew Kristian Wachtell, Eva Gerdts, Kurt Boman. Markku Nieminen, 
Vaslhos Papademetriou. Jens Rokkedal, Steven Snapinn, Peter Aurup, Bjorn Dahlof, 
Weill Cornell Medical Center, New York, NY 
Background: Left ventricular hypenrophy (LVH) predicts cardiovascular (CV) compltca- 
tions of hypertension, but it is not fully documented whether LVH regression during anti- 
hypertensive treatment modifies that risk Independent of blood pressure (BP) change or 
therapy durmg follow-up. Methods: Echocardiograms were performed at enrollment in 
the Losarian Intervention For Endpoint reduction in hypertension (LIFE) tnal and annually 
during 4.8 years mean follow-up for CV events in 960 prospectively patients with essen- 
tial hypertension and electrocardiographic LVH. Results: The primary endpoint, a com- 
posite of CV death, non-fatal myocardial infarction or stroke, occurred in 107 patients. In 
Cox regression models controlling for treatment type and baseline and in-treatment BP, 
there was a strong association between absence of LVH as a tlme-varying covariate and 
reduced rate of the composite CV endpoint (hazard ratio [HR]=0.58 for absence versus 
presence of LVH, 95% Cl=O.38-0.86, p=O.O09). There were parallel associations 
between absence of LVH and lower CV mortality (34 events, HR=0.34, 95% CI=O.17- 
0.71, p=O.OOl), stroke (61 events, HR=0.72, 95% Cl = 0.42-1.24, p=O.240), myocardial 
InfarctIon (39 events, HR~0.48, 95% Cl=O.24-0.93. p=O.O31) and all-cause death (77 
events, HR=0.36, 95% Cl 0.023-0.59, p-=0.001), independent of systolic BP and 
assigned treatment. Conclusion: Regression or prevention of anatomic LVH detected by 
echocardiography during antihypertensive treatment predicts a lower rate of CV events, 
independent of degree of BP lowering and treatment modality in essential hypertension. 
Our data further suggest that regression or prevention of LVH during antihypertensive 
treatment may be more closely linked to prognosis than the level of BP. 
